Brimonidine

NASHVILLE, Tenn. — A preservative-free brimonidine tartrate ophthalmic solution was statistically noninferior to Bausch + Lomb’s Lumify, offering an alternative option for ocular redness relief, according to a poster at Optometry’s Meeting.

The FDA has accepted a new drug application for PDP-716 for the treatment of glaucoma, according to a press release from Visiox Pharma.

The first of two pivotal phase 3 trials that will assess the safety and efficacy of Brimochol PF for the treatment of presbyopia is underway, according to a press release from Visus Therapeutics.

The first patients have been dosed in a phase 2 clinical trial investigating Brimochol for the treatment of presbyopia, according to a press release from Visus Therapeutics.

Dry eye disease and glaucoma both increase in prevalence with age. They are also commonly present in the patient who presents for cataract surgery.

Not a day goes by at SkyVision without a referral from a colleague who has come to wits’ end trying to manage the care of a patient who has dry eye disease.

Glaucoma-related ocular surface disease is a significant and often underdiagnosed ocular comorbidity that can significantly affect quality of life.

Visus Therapeutics has started a clinical development program for an eye drop designed to restore loss of near vision due to presbyopia, according to a press release.

Ocugen has completed 50% of enrollment for a phase 3 trial of OCU300 for the treatment of ocular redness and discomfort in patients with ocular graft-versus-host disease, according to a press release.